Grifols, a Spanish multinational pharmaceutical and chemical manufacturer, completed the acquisition of an 89.88% stake in Biotest, a biotechnology company, for $1.2bn. “This unique opportunity will allow Grifols and Biotest to mark a new milestone while shaping the plasma industry. It will enlarge our existing portfolio of plasma-derived therapies and fast-track the development of new products, with a concerted focus on delivering value to patients, shareholders and other key stakeholders. We look forward to partnering with the Biotest team," Raimon Grífols Roura, Grifols co-CEO.